Solvay SA
http://www.solvaypharmaceuticals-us.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Solvay SA
Multiple Chinese Firms Expand Global Phase III Trials To Japan
The efforts add up to a new trend after Chinese pharma firms embarked on a quest to launch pivotal Phase II or III trials worldwide, especially in the US and Europe, over the past decade. Meanwhile, BeiGene, Hengrui and others are advancing late-stage programs in the US.
Intarcia’s Exenatide Implant Rejected Again As US FDA Denies Comparative Safety Argument
Principal deputy commissioner Bumpus agrees with advisory committee findings that safety issues with ITCA 650 preclude approval, regardless of comparisons to other diabetes treatments. Final order caps a nearly eight-year regulatory saga that has grown increasingly rancorous.
Wave Chasing Huntington’s Accelerated Approval Based On Caudate Atrophy Surrogate
The biotech plans a pivotal trial that would support accelerated approval of the Takeda-partnered antisense oligonucleotide, WVE-003, and will discuss it with regulators before the end of the year.
Wave Plans To Pursue Accelerated Approval For Huntington’s Drug
The biotech said it plans to engage with regulators before the end of the year for the Takeda-partnered antisense oligonucleotide, WVE-003, to discuss a pivotal trial that would support accelerated approval.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Laboratories Ireland Ltd.
- Innogenetics nv
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice